CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Virpax Pharmaceuticals, Inc. - VRPX CFD

1.68
33.33%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.06
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02629 %
Charges from full value of position ($-5.00)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02629%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004068 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004068%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 1.26
Open 1.38
1-Year Change 51.65%
Day's Range 1.38 - 2.16
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 19, 2024 1.68 0.33 24.44% 1.35 2.37 1.29
Jul 18, 2024 1.26 -0.15 -10.64% 1.41 1.45 1.24
Jul 17, 2024 1.44 0.07 5.11% 1.37 1.48 1.33
Jul 16, 2024 1.47 0.38 34.86% 1.09 1.71 1.07
Jul 15, 2024 1.06 -0.24 -18.46% 1.30 1.30 1.03
Jul 12, 2024 1.36 -0.16 -10.53% 1.52 1.52 1.28
Jul 11, 2024 1.65 -0.04 -2.37% 1.69 2.06 1.36
Jul 10, 2024 1.65 -0.40 -19.51% 2.05 3.36 1.56
Jul 9, 2024 1.13 0.08 7.62% 1.05 1.23 0.98
Jul 8, 2024 1.06 0.38 55.88% 0.68 1.33 0.64
Jul 5, 2024 0.56 0.06 12.00% 0.50 0.56 0.50
Jul 3, 2024 0.50 0.01 2.04% 0.49 0.53 0.49
Jul 2, 2024 0.51 0.00 0.00% 0.51 0.51 0.50
Jul 1, 2024 0.48 -0.02 -4.00% 0.50 0.50 0.47
Jun 28, 2024 0.49 0.01 2.08% 0.48 0.50 0.48
Jun 27, 2024 0.49 0.01 2.08% 0.48 0.50 0.48
Jun 26, 2024 0.48 0.00 0.00% 0.48 0.49 0.47
Jun 25, 2024 0.48 0.00 0.00% 0.48 0.49 0.48
Jun 24, 2024 0.49 -0.01 -2.00% 0.50 0.51 0.48
Jun 21, 2024 0.53 0.04 8.16% 0.49 0.56 0.49

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Virpax Pharmaceuticals, Inc. Company profile

Founded in 2016, Virpax Pharmaceuticals (VRPX) is a preclinical stage biopharmaceutical company that develops and manufactures novel and proprietary drug delivery systems for non-opioid and non-addictive pain treatments.

Based in Berwyn, Pennsylvania, US, Virpax has global rights to the following patented pain management technologies:

  • Epoladerm – A topical nonsteroidal anti-inflammatory drug candidate for treatment of chronic osteoarthritis of the knee. It is used once a day.

  • Probudur – Injectable local anaesthetic Lipoal Gel Technology for postoperative pain management. The company plans to market this drug candidate to general surgeons, anesthesiologists and orthopaedic surgeons with the local anaesthetic postsurgical market, valued at $577m (£451m) as of 2019. The company believes Probudur can eliminate the need for opioids for postoperative pain relief.

  • Envelta – A Molecular Envelope Technology (MET) that delivers enkephalin for the management of acute and chronic pain, including cancer-induced pain, using an intranasal device. Virpax has identified a significant unmet need and market opportunity for current opioid prescribers, such as pain and hospice treatment centres.

  • AnQlar – A nasal spray that is being developed as an anti-viral barrier to potentially prevent or reduce the severity of viral infections in humans. The company has completed toxicology and ex-vivo studies on AnQlar, which show a reduction in infectivity from respiratory viruses such as influenza and SARS-CoV-2.

  • VRP324 – An investigational formulation designed to improve cannabidiol (CBD) transport to the brain via the nasal route. VRP324 propels the CBD powder formulation into the nose and into the brain via the olfactory nerve/bulb using a preassembled device and cartridge. This product candidate can potentially treat seizures associated with tuberous sclerosis complex (TSC), Lennox-Gastaut syndrome and Dravet syndrome in patients aged one year and older. CBD is a substance found in cannabis.

Virpax went public on 16 February 2021. Its stock is listed on the Nasdaq capital market under the ticker symbol ‘VRPX’.

Industry: Biotechnology & Medical Research (NEC)

1055 Westlakes Drive, Suite 300
BERWYN
PENNSYLVANIA 19312
US

People also watch

ETH/USD

3,521.04 Price
+0.530% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

19,627.10 Price
+0.540% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

68,009.20 Price
+0.290% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,403.67 Price
+0.220% 1D Chg, %
Long position overnight fee -0.0198%
Short position overnight fee 0.0116%
Overnight fee time 21:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading